Gastrointestinal malignancies harbor actionable MET exon 14 deletions
Jeeyun Lee(Samsung Medical Center), Kyoung‐Mee Kim(Samsung (South Korea))
Cited by 61
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
|Clinical Cancer Research|2019|237
Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers
|Frontiers in Immunology|2018|103
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|Seoul National University Open Repository (Seoul National University)|2021|95